Accessibility Menu
Cannabis Bioscience International logo

Cannabis Bioscience International(OTC) CBIH

Market Cap$1.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2018)-99%
5 Year-90%
1 Year-73%
1 Month-40%
$0.00
+0%
+0.00Today
Cannabis Bioscience International last closing stock price
MetricPriceDate
Last closeUSD 0.002026-07-29
Cannabis Bioscience International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+50%USD 0.002026-07-22
1 month-40%USD 0.002026-06-29
3 month-50%USD 0.002026-04-30
Year to date-70%USD 0.002025-12-31
1 year-72.73%USD 0.002025-07-29
3 year-66.67%USD 0.002023-07-28
5 year-90.32%USD 0.002021-07-30
Since inception-99.19%USD 0.022018-07-24

Cannabis Bioscience International Financials at a Glance

Market Cap

$1.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$123.63K

Net Income (TTM)

-$515.29K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.50 (Low)

Price

$0.00

Volume

500,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Apr 20, 2026

CBIH News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cannabis Bioscience International

Cannabis Bioscience helps doctors and patients learn about medical cannabis. Its clinical trials study treatments for sleep and fertility issues. The company also sells educational courses and consulting services to healthcare professionals.

What’s in the Medicine Cabinet? (Products and Services)

  • Clinical Trials: Research studies on medical cannabis, mainly for sleep and fertility (99.7% of Q1 2025 revenue).
  • Medical Cannabis Education: Online and in-person courses for healthcare workers and the public.
  • Consulting Services: Advice for clinics and businesses on medical cannabis use and regulations (0% of Q1 2025 revenue).
  • Merchandise Sales: Small-scale sales of cannabis-related products (0.3% of Q1 2025 revenue).
  • Digital Publishing: Educational materials and resources for medical cannabis professionals.

Growth Spurts and Growing Pains (Growth and Expansion)

  • Launched online education platform, expanding global reach (year not specified).
  • Entered Latin American markets through Pharmacology University (timeline not specified).
  • Added clinical trial services via Alpha Research Institute (timeline not specified).
  • Expanded business model to include franchising and consulting (timeline not specified).

Why This Company Isn’t Just Blowing Smoke (What Makes Cannabis Bioscience Special)

The company combines clinical research, education, and product sales in one business. Its focus on sleep and fertility sets it apart from broader healthcare firms. Online platforms allow it to reach clients in the US, Latin America, and beyond.

Five Things You Need to Know (Financial Highlights)

  • Revenue was $24,200 in Q1 2025, down 86.5% from Q1 2024.
  • Clinical trials made up 99.7% of Q1 2025 revenue.
  • Operating loss improved 23.4% to $74,784 in Q1 2025.
  • Cash balance was $223 as of August 31, 2025.

Bottom Line

Cannabis Bioscience has shifted from education to clinical trials as its main business. The company faces high customer concentration and ongoing financial challenges.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

2

CEO

Dante Picazo

Website

www.cbih.net

Headquarters

Houston, TX 77036, US

CBIH Financials

Key Financial Metrics (TTM)

Gross Margin

-0.06%

Operating Margin

-312.80%

Net Income Margin

-416.81%

Return on Equity

39.33%

Return on Capital

N/A

Return on Assets

-33373.58%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

11.63B

Volume

500.00K

Avg. Volume

10.56M

Financials (TTM)

Gross Profit

-$80.00

Operating Income

-$386.71K

EBITDA

-$303.56K

Operating Cash Flow

-$243.78K

Capital Expenditure

-$4.97

Free Cash Flow

-$243.78K

Cash & ST Invst.

$90.00

Total Debt

$406.14K

Cannabis Bioscience International Performance Analysis

Cannabis Bioscience International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-05-31USD 214,980N/A
20232023-05-31USD 316,82547.4%
20242024-05-31USD 248,841-21.5%
20252025-05-31USD 303,02221.8%
Cannabis Bioscience International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31134.1%
Q12025-08-31-30.8%
Q22025-11-30120.1%
Q32026-02-28-79.0%
Cannabis Bioscience International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-05-31USD -0.00N/A
20232023-05-31USD -0.000.0%
20242024-05-31USD -0.000.0%
20252025-05-31USD 0.00N/A
Cannabis Bioscience International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42025-05-31-6.5%
Q12025-08-3164.1%
Q22025-11-30100.0%
Q32026-02-28N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2025YOY CHG

Revenue

$11.21K

-25.0%

Gross Profit

-$40.79K

-813.6%

Gross Margin

-3.64%

N/A

Market Cap

$1.74MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$872.00K

N/A

Employees

2

N/A

Net Income

-$103.93K

+42.7%

EBITDA

-$93.26K

+37.8%

Quarterly Fundamentals

Name
Q3 2025YOY CHG

Total Cash

$90.00

-83.6%

Total Debt

$406.14K

-5.1%

Accounts Receivable

$1.27K

-52.0%

Inventory

$0.00

N/A

Long Term Debt

$249.50K

-9.5%

Short Term Debt

$156.64K

-5.2%

Return on Assets

-333.74%

N/A

Return on Invested Capital

31.76%

N/A

Free Cash Flow

-$14.60K

+93.5%

Operating Cash Flow

-$14.60K

+93.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
DHBUFDelivra Health Brands Inc.
$0.09+4.43%
BUDZWEED, Inc.
$0.02-9.50%
AYRWFAyr Wellness Inc.
$0.00+0.00%
AUSAFAustralis Capital Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.84+0.13%
NOKNokia
$8.99+0.07%
MSFTMicrosoft
$455.11+0.17%
NVDANvidia
$193.72+0.02%

Questions About CBIH

What is the current price of Cannabis Bioscience International?

Cannabis Bioscience International is trading at $0.00 per share.

What is the 52-week range for Cannabis Bioscience International?

Over the past 52 weeks, Cannabis Bioscience International has traded between $0.00 and $0.00.

How much debt does Cannabis Bioscience International have?

As of the most recent reporting period, Cannabis Bioscience International reported total debt of $406.14K.

How much cash does Cannabis Bioscience International have on hand?

Cannabis Bioscience International reported $90.00 in cash and cash equivalents in its most recent financial results.

What is Cannabis Bioscience International’s dividend yield?

Cannabis Bioscience International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services